Microplate-based automatic blood grouping analyzer Metis of Aikang MedTech Co., Ltd. (henceforth referred to as Aikang) received approval for marketing in 2015; and its MGT-based automatic blood grouping analyzer Aigel received approval for marketing in 2016.

Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

The National Comprehensive Cancer Network on Tuesday published new guidelines for treating children with brain cancer, underscoring the importance of broad molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for patients.

Recently, Shanghai University, relying on Shanghai's scientific and educational resources, gave full play to the cross-integration of multiple disciplines such as machinery and control, and the national first-class discipline of "mechanical engineering"

Biomarker discovery firm Sapient said Monday that it has received a $9.2 million grant from the Bill & Melinda Gates Foundation for mass spectrometry-based metabolomic biomarker studies.

Hologic and Thermo Fisher Scientific announced separately on Monday that they have received CE-IVD marking for their respective RT-PCR-based respiratory virus assays.

Zhiyan Consulting Data Center released the net profit ranking of Chinese medical device listed companies in the first quarter of 2022, ranking 109 Chinese listed medical companies according to their net profit in the first quarter of 2022.

Color Health said on Friday that it has partnered with the US Centers for Disease Control and Prevention to increase access to no-cost, PCR-based, COVID-19 testing.

Quest Diagnostics said Thursday that it is participating in the Centers for Disease Control and Prevention's (CDC) Increasing Community Access to Testing (ICATT) for COVID-19 program.

How did Chinese listed companies perform in the first half of the year? As of June 30, 2022, a total of 8,392 Chinese listed companies have been listed on 16 major exchanges in the world, including Shanghai, Shenzhen, Beijing, Hong Kong and New York.

Meridian Bioscience announced on Thursday that it has entered into an agreement to be acquired by a newly formed affiliate of Korean diagnostic company SD Biosensor and investment firm SJL Partners for about $1.53 billion.

MirXes, a Singapore-based RNA testing firm, said on Thursday it has signed a memorandum of understanding with several Singapore universities and hospitals to launch a study of circulating microRNA and DNA methylation biomarkers for multi-cancer early detection.